ClinicalTrials.gg
RecruitingNCT07438951ONWARDUpdated Oct 26, 2026

Efficacy and Safety of a Nitric Oxide Generating Dressing for Diabetic Foot Ulcers (ONWARD)

An observational study in Diabetic Foot Ulcers (DFUs), sponsored by ConvaTec Inc.. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by ConvaTec Inc. · Observational

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 26, 2026Now RecruitingFirst site in United Kingdom+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
102
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 60 studies in Diabetic Foot with a site in United Kingdom — 5 open to participants now, 8 under way, none of them phase 3. Diabetic Foot · United Kingdom.

Planned enrollment
7th of 15
102 · median 100
Started
2026
the only one that year
Observational
15 of 60
3 open now
Registered
60th of 60
by date
Lead sponsor
2 of 60
ConvaTec Inc.

Among the 60 studies in Diabetic Foot with a site in United Kingdom, this one is the 7th largest by planned enrollment of the 15 observational ones that give a count, is the only one that started in 2026, is one of 15 observational ones, and was the 60th registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

5 of the 60 studies in Diabetic Foot with a site in United Kingdom are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Diabetic Foot with a site in United Kingdom, or all of them as a file.
02

Study summary

Real world evidence study on the performance and safety of a nitric oxide generating dressing on the treatment of diabetic foot ulcers

03

Conditions studied

  • Diabetic Foot Ulcers (DFUs)

Keywords

  • Diabetic foot ulcers
  • Nitric Oxide
  • Wound
  • dressing
  • Woundcare
04

Who can participate

The criteria were revised on the registry on Oct 26, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

All subjects over the age of 18 years with a non-healing DFU (defined as failing to progress on a healing trajectory in the previous 4 weeks prior to enrolment) and treated with ConvaNiox (EDX110) will be screened for eligibility based on medical record review and discussions with the subject and their treating physician.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

IC-1 - Subjects at least 18 years old and willing to participate in all procedures and follow-up evaluations necessary to complete the study

IC-2 - The subject must have either type 1 or type 2 diabetes and a diabetes-related ulcer meeting all the following characteristics:

IC-2a Classified as University of Texas (UT) Classification Grade 1 stages A-D IC-2b At or below the level of malleolus IC-2c Neuropathic or neuroischemic etiology confirmed through Electronic Medical Records (EMR) IC-2d Ulcer surface area between ≥1 and ≤25 cm² IC-2e For subjects who have more than one ulcer, the largest ulcer will be the study ulcer

IC-3 Non-infected and infected ulcers are eligible for inclusion, with infection being classified using the International Working Group on the Diabetic Foot (IWGDF) Infection guidelines.

Only PEDIS 2 infections are permitted. Mild superficial skin and soft tissue infections with no systemic manifestations, characterized by erythema >0.5 but \<2 cm from the wound margin and/or other local signs of infection (swelling, induration, tenderness, increased warmth, or purulent discharge), without involvement of deeper tissues (e.g., tendon, muscle, joint, or bone).

IC-4 Adequate arterial supply in the lower extremity as defined by Wound, Ischemia, foot Infection (WIfI) Ischemia grade 0-1;

  1. Palpable foot pulse with biphasic or triphasic pedal Doppler waveforms, AND
  2. Ankle Brachial Index (ABI) >0.6 OR Toe Brachial Index (TBI) >0.5, OR
  3. Toe pressure >40mmHg

Exclusion criteria

Exclusion Criteria:

EC-1 Ulcers that are tunnelling or have cavities (>10mm in depth)

EC-2 An ulcer that is actively bleeding. Subjects may be re-screened once active bleeding has stopped

EC-3 Subjects taking any medication known to inhibit wound closure including chemotherapy and immunomodulatory biological agents. The use of systemic \<10mg/day is permitted

EC-4 Active Charcot foot

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
102 participants (estimated)
Patient registry
No

Groups and cohorts

  • Subjects with non-healing diabetes-related foot ulcers, treated with ConvaNiox

    Device: ConvaNiox

Interventions

  • DeviceConvaNiox

    At each visit subjects will receive their Standard of Care (SoC) treatment for their DFU, but instead of their normal primary dressing they will receive an application of ConvaNiox (EDX110).

06

What researchers measure

Primary outcomes

  1. Percentage area reduction

    Difference between wound area at day 0 and 12 weeks of treatment

    Time frame: at 12 weeks

Secondary outcomes

  1. Incidence of wound closure

    Difference between wound area at day 0 and 12 weeks of treatment

    Time frame: at 12 weeks

  2. Percentage area reduction

    Difference between wound area at day 0 and 4 weeks of treatment

    Time frame: at 4 weeks

  3. Incidence of >50% percentage area reduction

    Difference between wound area at day 0 and 4 weeks of treatment

    Time frame: at 4 weeks

07

Study locations

1 of 1 sites recruiting
  • Tameside and Glossop Integrated Care NHS Foundation Trust
    Ashton-under-Lyne, England OL6 9RW, United Kingdom
    Recruiting
    • · Contact0161 922 6000
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Sep 2027, 12 months after the start.

Of 90 observational studies under Diabetic Foot, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 59. This study's planned 12 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Sep 2026, on Oct 26, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2026
First posted
Feb 27, 2026
StartActual
Sep 1, 2026was Jul 2026
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 26, 2026
Sites
1 site added — first site in United Kingdom
Show site
  • Tameside and Glossop Integrated Care NHS Foundation Trust · Ashton-under-Lyne, United Kingdom
Oct 26, 2026
Start date
Jul 2026→Sep 1, 2026 (actual)
Oct 26, 2026
Eligibility
1 inclusion criterion added, 2 removed; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • RemovedOnly PEDIS 2 infections are permitted - Mild superficial skin and soft tissue infections with no systemic manifestations and involving:
  • RemovedErythema extending ≥2 cm from the wound margin, and/or tissue deeper than skin and subcutaneous tissues (e.g., tendon, muscle, joint, and bone)
  • AddedOnly PEDIS 2 infections are permitted. Mild superficial skin and soft tissue infections with no systemic manifestations, characterized by erythema >0.5 but <2 cm from the wound margin and/or other local signs of infection (swelling, induration, tenderness, increased warmth, or purulent discharge), without involvement of deeper tissues (e.g., tendon, muscle, joint, or bone).
Exclusion criteria
  • EditedEC-3 Subjects taking any medication known to inhibit wound closure including chemotherapy and immunomodulatory biological agents. The use of systemic corticosteroids <10mg/kg/day is permitted
Oct 26, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionPercentage area reduction: how it is measured was reworded
Oct 26, 2026
Secondary outcomes
3 description edited
What changed in the outcomes
  • DescriptionIncidence of >50% percentage area reduction: how it is measured was reworded
  • DescriptionIncidence of wound closure: how it is measured was reworded
  • DescriptionPercentage area reduction: how it is measured was reworded
Oct 26, 2026
Contact
Study contact changed: added c•••@convatec.com. See the current contact
Oct 26, 2026
Title
A Study on the Efficacy and Safety of a Nitric Oxide Generating Dressing in the Treatment of Diabetes Relatedfor Diabetic Foot Ulcers. (ONWARD)
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United Kingdom
    Show site
    • Tameside and Glossop Integrated Care NHS Foundation Trust · Ashton-under-Lyne, United Kingdom
    Start date Jul 2026→Sep 1, 2026 (now actual)
    Eligibility 1 inclusion criterion added, 2 removed; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • RemovedOnly PEDIS 2 infections are permitted - Mild superficial skin and soft tissue infections with no systemic manifestations and involving:
    • RemovedErythema extending ≥2 cm from the wound margin, and/or tissue deeper than skin and subcutaneous tissues (e.g., tendon, muscle, joint, and bone)
    • AddedOnly PEDIS 2 infections are permitted. Mild superficial skin and soft tissue infections with no systemic manifestations, characterized by erythema >0.5 but <2 cm from the wound margin and/or other local signs of infection (swelling, induration, tenderness, increased warmth, or purulent discharge), without involvement of deeper tissues (e.g., tendon, muscle, joint, or bone).
    Exclusion criteria
    • EditedEC-3 Subjects taking any medication known to inhibit wound closure including chemotherapy and immunomodulatory biological agents. The use of systemic corticosteroids <10mg/kg/day is permitted
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionPercentage area reduction: how it is measured was reworded
    Secondary outcomes 3 description edited
    What changed in the outcomes
    • DescriptionIncidence of >50% percentage area reduction: how it is measured was reworded
    • DescriptionIncidence of wound closure: how it is measured was reworded
    • DescriptionPercentage area reduction: how it is measured was reworded
    Contact Study contact changed: added c•••@convatec.com. See the current contact
    Title A Study on the Efficacy and Safety of a Nitric Oxide Generating Dressing in the Treatment of Diabetes Relatedfor Diabetic Foot Ulcers. (ONWARD)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07438951
Lead sponsor
ConvaTec Inc.
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Sep 1, 2026
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Oct 26, 2026

Study contacts

Andrew Thomas
Contact
andrew.thomas@convatec.com
+44 (0) 7791904279
Claudia Schroeder
Contact
claudia.schroeder@convatec.com
Christina Mastandrea
study director · Medical & Clinical Affairs

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion